Literature DB >> 17086359

Neutrophil activator of matrix metalloproteinase-2 (NAM).

Ellen E Rollo1, Michelle Hymowitz, Cathleen E Schmidt, Steve Montana, Hussein Foda, Stanley Zucker.   

Abstract

We have isolated a novel soluble factor(s), neutrophil activator of matrix metalloproteinases (NAM), secreted by unstimulated normal human peripheral blood neutrophils that causes the activation of cell secreted promatrix metalloproteinase-2 (proMMP-2). Partially purified preparations of NAM have been isolated from the conditioned media of neutrophils employing gelatin-Sepharose chromatography and differential membrane filter centrifugation. NAM activity, as assessed by exposing primary human umbilical vein endothelial cells (HUVEC) or HT1080 cells to NAM followed by gelatin zymography, was seen within one hour. Tissue inhibitor of metalloproteinase-2 (TIMP-2) and hydroxamic acid derived inhibitors of MMPs (CT1746 and BB94) abrogated the activation of proMMP-2 by NAM, while inhibitors of serine and cysteine proteases showed no effect. NAM also produced an increase in TIMP-2 binding to HUVEC and HT1080 cell surfaces that was inhibited by TIMP-2, CT1746, and BB94. Time-dependent increases in MT1-MMP protein and mRNA were seen following the addition of NAM to cells. These data support a role for NAM in cancer dissemination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17086359     DOI: 10.1007/s10585-006-9035-9

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  22 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.

Authors:  A Falanga; M Marchetti; V Evangelista; A Vignoli; M Licini; M Balicco; S Manarini; G Finazzi; C Cerletti; T Barbui
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

3.  Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma.

Authors:  D Moutsiakis; P Mancuso; H Krutzsch; W Stetler-Stevenson; S Zucker
Journal:  Connect Tissue Res       Date:  1992       Impact factor: 3.417

4.  Neutrophil-derived serine proteinases enhance membrane type-1 matrix metalloproteinase-dependent tumor cell invasion.

Authors:  P Shamamian; B J Pocock; J D Schwartz; S Monea; N Chuang; D Whiting; S G Marcus; A C Galloway; P Mignatti
Journal:  Surgery       Date:  2000-02       Impact factor: 3.982

5.  Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells.

Authors:  Andries Zijlstra; Marco Seandel; Tatyana A Kupriyanova; Juneth J Partridge; Mark A Madsen; Elizabeth A Hahn-Dantona; James P Quigley; Elena I Deryugina
Journal:  Blood       Date:  2005-09-20       Impact factor: 22.113

6.  Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis.

Authors:  P Shamamian; J D Schwartz; B J Pocock; S Monea; D Whiting; S G Marcus; P Mignatti
Journal:  J Cell Physiol       Date:  2001-11       Impact factor: 6.384

7.  Activity and tissue localization of cathepsin G in non small cell lung cancer.

Authors:  T Maksimowicz; E Chyczewska; L Chyczewski; J Nikliński; H Ostrowska; J Szyszko; M Furman
Journal:  Rocz Akad Med Bialymst       Date:  1997

Review 8.  Role of pericellular proteolysis by membrane-type 1 matrix metalloproteinase in cancer invasion and angiogenesis.

Authors:  Motoharu Seiki; Naohiko Koshikawa; Ikuo Yana
Journal:  Cancer Metastasis Rev       Date:  2003 Jun-Sep       Impact factor: 9.264

Review 9.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

10.  Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.

Authors:  J Yamashita; M Ogawa; K Sakai
Journal:  Surgery       Date:  1995-06       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.